News & Updates

A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.

DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.

High expression of Wilms’ tumor 1-associating protein (WTAP) in patients with nonsmall cell lung cancer (NSCLC) appears to promote poor clinical outcomes, suggests a study.

Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.

A study conducted among Vietnamese women found that engaging in regular exercise leads to a reduction in the overall risk of breast cancer, especially the HER2-enriched subtype.

Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).